Antitumor activity of HM781-36B, a highly effective pan-HER inhibitor in erlotinib-resistant NSCLC and other EGFR-dependent cancer models-Reference-Cited by-同舟云学术

Antitumor activity of HM781-36B, a highly effective pan-HER inhibitor in erlotinib-resistant NSCLC and other EGFR-dependent cancer models

Published:2011-08-24 Issue:10 Volume:130 Page:2445-2454
ISSN:0020-7136
Container-title:International Journal of Cancer
language:en
Short-container-title:Int. J. Cancer

Author:

Cha Mi Young,Lee Kwang-Ok,Kim Mira,Song Ji Yeon,Lee Kyu Hang,Park Jongmin,Chae Yun Jung,Kim Young Hoon,Suh Kwee Hyun,Lee Gwan Sun,Park Seung Bum,Kim Maeng Sup

Publisher

Wiley

Subject

Cancer Research,Oncology

Reference48 articles.

1. Cell signaling by receptor tyrosine kinases;Schlessinger;Cell,2000

2. ERBB receptors and cancer: the complexity of targeted inhibitors;Hynes;Nat Rev Cancer,2005

3. Untangling the ErbB signaling network;Yarden;Nat Rev Mol Cell Biol,2001

4. EGFR tyrosine kinase domain mutations are detected in histologically normal respiratory epithelium in lung cancer patients;Tang;Cancer Res,2005

5. Epidermal growth factor receptors as a target for cancer treatment: the emerging role of IMC-C225 in the treatment of lung and head and neck cancers;Herbst;Semin Oncol,2002

Cited by 73 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The Association between NADPH Oxidase 2 (NOX2) and Drug Resistance in Cancer;Current Cancer Drug Targets;2024-12

2. Unraveling the future: Innovative design strategies and emerging challenges in HER2-targeted tyrosine kinase inhibitors for cancer therapy;European Journal of Medicinal Chemistry;2024-10

3. Current status and breakthroughs in treating advanced non-small cell lung cancer with EGFR exon 20 insertion mutations;Frontiers in Immunology;2024-05-07

4. A phase I dose-escalation study of pulsatile afatinib in patients with recurrent or progressive brain cancer;Neuro-Oncology Advances;2024-01-01

5. To Investigate Growth Factor Receptor Targets and Generate Cancer Targeting Inhibitors;Current Topics in Medicinal Chemistry;2023-12